Journal
WORLD JOURNAL OF CLINICAL ONCOLOGY
Volume 12, Issue 3, Pages 164-182Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.5306/wjco.v12.i3.164
Keywords
Triple negative breast cancer; Immunotherapy; Poly (adenosine diphosphate-ribose) polymerase inhibitors; Breast cancer
Categories
Ask authors/readers for more resources
Metastatic triple negative breast cancer is aggressive and chemotherapy shows the best responses in the first line. Recent studies have shown improved progression free survival with the combination of atezolizumab/pembrolizumab and chemotherapy in PD-L1 positive metastatic TNBC patients, although another study found no benefit with atezolizumab and paclitaxel. Treatment with Olaparib or Talazoparib in BRCA-associated metastatic TNBC patients showed benefit in progression free survival but not in overall survival.
Metastatic triple negative breast cancer (TNBC) has an aggressive phenotype with a predilection for visceral organs and brain. Best responses to chemotherapy are predominately in the first line. Recent studies have demonstrated improved progression free survival with the combination of atezolizumab/pembrolizumab and chemotherapy in programmed death-ligand 1 positive metastatic TNBC. However, a recent trial in a similar population showed no benefit for atezoli-zumab and paclitaxel which led to a Food and Drug Administration alert. Two phase III trials (OLYMPIAD and BROCADE3) demonstrated a benefit in progression free survival (PFS) but not overall survival in patients with BRCA-associated metastatic TNBC treated with Olaparib or Talazoparib respectively. For those treated with Talazoparib, the time to deterioration in health related-quality of life was also longer compared to chemotherapy. The BROCADE3 trial demonstrated that the combination of a platinum and veliparib increased PFS in first-line metastatic TNBC but at the cost of increased toxicity. There are no head-to-head comparisons of a poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) and platinums. There are unanswered questions regarding the role of PARPi maintenance after platinum therapy as is standard of care in BRCA-associated ovarian cancer. Other areas of therapeutic interest include targeting aberrations in the phosphoinositide 3-kinase pathway, protein kinase B, mammalian target of rapamycin or utilising antibody drug conjugates. This review focusses on recent and emerging therapeutic options in metastatic TNBC. We searched PubMed, clinicaltrials.gov and recent international meetings from American Society of Clinical Oncology, San Antonio Breast Cancer Conference and the European Society of Medical Oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available